Radiation induces an EGFR-dependent lactate-epigenetic program underlying synergy with EGFR inhibition
Open Access
- 4 July 2026
- journal article
- Published by Springer Nature in Cellular Oncology
- Vol. 49 (5)
Abstract
Clinical studies have suggested a therapeutic synergy between EGFR-TKIs and radiotherapy; however, the underlying mechanisms remain incompletely understood, particularly in tumors harboring the acquired resistance mutation EGFR T790M. Using EGFR T790M-positive cell lines, patient-derived organoids (PDOs), and patient-derived xenograft (PDX) models, we systematically investigated radiation responses in EGFR T790M-mutant tumors. Metabolic profiling, protein interaction and phosphorylation analyses, enzyme activity assays, chromatin immunoprecipitation sequencing (ChIP-seq), and DNA damage repair assessments were performed to elucidate the molecular mechanisms of therapeutic synergy between EGFR-TKIs and radiotherapy. We show that EGFR T790M drives a radiation-amplified glycolytic program characterized by enhanced intracellular lactate accumulation. Radiation induces EGFR-dependent tyrosine phosphorylation and activation of lactate dehydrogenase A (LDHA), sustaining lactate production. Rather than being rapidly exported or oxidized, lactate is retained intracellularly and promotes histone H3 lysine lactylation (H3Kla) at promoter regions of DNA repair genes, establishing a repair-permissive chromatin state. This epigenetic priming enhances repair complex assembly, accelerates recruitment of repair factors to DNA double-strand breaks, and facilitates efficient DNA damage resolution. Genetic or pharmacological disruption of the LDHA-lactate axis impairs DNA repair and restores radiosensitivity. In EGFR T790M PDX models, targeting this metabolic pathway significantly enhances radiotherapy efficacy with acceptable toxicity. Our findings identify a previously unrecognized metabolic-epigenetic-repair axis through which EGFR T790M promotes radiotherapy resistance. This study redefines the functional role of EGFR T790M in radiation biology, provides mechanistic insight into the clinical synergy between EGFR inhibition and radiotherapy, and offers a rational framework for developing metabolism-informed combination radiotherapy strategies.Keywords
Funding Information
- National Natural Science Foundation of China (82473378)
- the Shanghai Pulmonary Hospital Research-Oriented Physician Talent Program (LYRC202407)
- Tongji University Medicine-X interdisciplinary Research Initiative (TJ-FK-YXJC022)
- Shanghai Municipal Health Commission Seed Funding Program for Research and Translation of New Medical Technologies (2025ZZ2011)
This publication has 47 references indexed in Scilit:
- Thoracic radiotherapy synergizes with first‐line EGFR ‐ TKIs in advanced EGFR ‐mutant NSCLC : A dual‐center real‐world studyInternational Journal of Cancer, 2025
- Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH studyAnnals of Oncology, 2025
- Stereotactic Radiation Therapy in Early Non–Small Cell Lung Cancer and Interstitial Lung DiseaseJAMA Oncology, 2024
- Non‐small cell lung cancer in ChinaCancer Communications, 2022
- Radiotherapy with continued EGFR‐TKIs for oligoprogressive disease in EGFR‐mutated non‐small cell lung cancer: A real‐world studyCancer Medicine, 2022
- A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapyAnnals of Oncology, 2020
- Therapeutic Effect of First-line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Combined with Whole Brain Radiotherapy on Patients with EGFR Mutation-positive Lung Adenocarcinoma and Brain MetastasesCurrent Medical Science, 2018
- Targeted sequencing and intracranial outcomes of patients with lung adenocarcinoma brain metastases treated with radiotherapyCancer, 2018
- A phase I open-labeled, single-arm, dose-escalation, study of dichloroacetate (DCA) in patients with advanced solid tumorsInvestigational New Drugs, 2015
- Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancerJournal of Cancer Research and Clinical Oncology, 2014